Elevation Oncology, Inc. (ELEV): Price and Financial Metrics


Elevation Oncology, Inc. (ELEV): $1.00

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ELEV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ELEV Stock Price Chart Interactive Chart >

Price chart for ELEV

ELEV Price/Volume Stats

Current price $1.00 52-week high $5.20
Prev. close $1.00 52-week low $0.72
Day low $0.96 Volume 23,003
Day high $1.03 Avg. volume 152,335
50-day MA $0.98 Dividend yield N/A
200-day MA $1.48 Market Cap 23.30M

Elevation Oncology, Inc. (ELEV) Company Bio


Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.


ELEV Latest News Stream


Event/Time News Detail
Loading, please wait...

ELEV Latest Social Stream


Loading social stream, please wait...

View Full ELEV Social Stream

Latest ELEV News From Around the Web

Below are the latest news stories about ELEVATION ONCOLOGY INC that investors may wish to consider to help them evaluate ELEV as an investment opportunity.

Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that…

PR Newswire | January 9, 2023

Elevation Oncology CEO resigns as part of company prioritization effort

Elevation Oncology (ELEV) CEO Shawn Leland has resigned amid a company effort to realign resources and prioritize pipeline assets.

Seeking Alpha | January 6, 2023

Elevation Oncology Inc. (NASDAQ:ELEV) Shares Rebounded -2.38% From Their Lows – But Can They Continue?

In recent trading session, Elevation Oncology Inc. (NASDAQ:ELEV) saw 0.66 million shares changing hands at last check today with its beta currently measuring 0. Company’s recent per share price level of $0.84 trading at -$0.21 or -20.05% at last check today assigns it a market valuation of $25.98M. That most recent trading price of ELEV’s … Elevation Oncology Inc. (NASDAQ:ELEV) Shares Rebounded -2.38% From Their Lows – But Can They Continue? Read More »

Marketing Sentinel | January 6, 2023

Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris

Yahoo | January 6, 2023

Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit

NEW YORK, Nov. 30, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Founder and Chief…

PR Newswire | November 30, 2022

Read More 'ELEV' Stories Here

ELEV Price Returns

1-mo 5.26%
3-mo -13.79%
6-mo -21.26%
1-year -77.12%
3-year N/A
5-year N/A
YTD 5.26%
2022 -84.22%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7062 seconds.